Sangamo BioSciences | SGMO - Cost Of Sales


Sangamo BioSciences reported 2.42M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
Bayer EUR 4.54B 692M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Cipla INR 29.71B 3.4B Jun/2026
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.82M 1.71M Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Gilead Sciences USD 1000M 445M Jun/2026
GlaxoSmithKline GBP 2.07B 192M Jun/2026
Grifols EUR 1.51B 184.45M Dec/2025
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
J&J USD 8.08B 80M Sep/2026
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Merck USD 3.14B 200M Jun/2026
Novartis USD 3.71B 251M Jun/2026
Omeros USD 33.16M 18.52M Jun/2024
Pfizer USD 4.09B 498M Jun/2026
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.02B 656M Jun/2026
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026